Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders;Prolongation du traitement par interféron pégylé et ribavirine à 72 semaines pour les malades ayant une hépatite C de génotype 1 répondeurs lents

Hepato-Gastro

Volumn 15, Issue 3, 2008, Pages 252-253

  Hézode, Christophe ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN;

DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NOTE; TREATMENT DURATION; VIROLOGY; VIRUS VIRULENCE;

EID: 45849104285     PISSN: 12537020     EISSN: None     Source Type: Journal    
DOI: 10.1684/hpg.2008.0216     Document Type: Note

References (4)

1. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncalves FL, Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005 ; 43 : 425-33.
2. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1 : comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 ; 130 : 1086-97.
3. Sanchez-Tapias JM, Diago M; Escartin P, Enriquez J, Romoreo-Gomez M, Bercena R, et al. Peginterferon-alfa 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 ; 131 : 451-60.
4. Buti M, Lurie Y, Blokhina N, Eteuber G, Halota W, Sumskiene J. Pegylated interferon alfa-2b plus ribavirin in patients with genotype 1 chronic hepatitis C with a slow virologic response: an early enrollers analysis of the Success study [abstract]. Hepatology 2006 ; 44 (Suppl) : 342A.